Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27165476 | 0.90 | ALDH1A1 (0.38) | GAATDP1KMT2ASMN1; SMN2HTT | |
| SCHEMBL17848825 | 0.83 | MEN1 (0.33) | GAATDP1KMT2AJAK2JAK1 | |
| SCHEMBL13655626 | 0.82 | ATM (0.45) | GAATDP1KMT2ASMN1; SMN2HTT | |
| SCHEMBL28395559 | 0.81 | ATM (0.43) | GAATDP1KMT2ASMN1; SMN2HTT | |
| SCHEMBL17848849 | 0.81 | JAK2 (0.33) | JAK2JAK1 | |
| SCHEMBL15832603 | 0.79 | ALDH1A1 (0.53) | GAAMAPTKMT2ASMN1; SMN2PHGDH | |
| SCHEMBL29969222 | 0.78 | CA2 (0.39) | GAAKMT2APOLBJAK2JAK1 | |
| SCHEMBL13655637 | 0.78 | L3MBTL1 (0.48) | GAAKMT2ASMN1; SMN2HTTPOLB | |
| SCHEMBL17820875 | 0.77 | USP2 (0.45) | KMT2ASMN1; SMN2 | |
| SCHEMBL19121772 | 0.76 | POLB (0.35) | GAATDP1KMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | GAA 1981/4885TDP1 3796/4885CYP1A2 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.